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Topical corticosteroids are eﬀective in reducing anterior segment inﬂammation but are associated with adverse drug reactions
(ADRs) including elevation of intraocular pressure (IOP) and cataract formation. Retrometabolic drug design has advanced the
developmentofnewcorticosteroidswithimprovedtherapeuticindices.Engineeredfromprednisolone,loteprednoletabonate(LE)
has a 17α-chloromethyl ester, in lieu of a ketone group, and a 17β-etabonate group. LE is highly lipophilic and binds with high
aﬃnity to the glucocorticoid receptor; any unbound LE is metabolized to inactive metabolites. LE has been studied in several
anterior segment inﬂammatory conditions (giant papillary conjunctivitis, allergic conjunctivitis, anterior uveitis, and keratocon-
junctivitis sicca), and in postoperative ocular inﬂammation and pain. Combined with tobramycin, it is eﬀective in blepha-
rokeratoconjunctivitis. Elevations in IOP are infrequent with LE, and the absence of a C-20 ketone precludes formation of Schiﬀ
base intermediates with lens proteins, a common ﬁrst step implicated in cataract formation with ketone steroids.
1.Introduction
The eye is vulnerable to damage from relatively low levels
of intraocular inﬂammation. The blood-aqueous and blood-
retinal barriers usually limit penetration of protein and
cells from the peripheral circulation, while regulatory mole-
c u l e sa n dc e l l si nt h ee y ea c t i v e l ys u p p r e s si m m u n o l o g i c
responses [1]. Nevertheless, ocular inﬂammatory conditions
and surgical trauma induce changes in the blood-aqueous
and blood-retinal barriers [1–3]. As a result, immune cells
and mediators of inﬂammation enter the eye, resulting in the
classical clinical signs and symptoms of ocular inﬂammation
including redness, pain, swelling, and itching [4]. Ocular
inﬂammation, if left untreated, may lead to temporary or
permanent loss of vision [5].
Topical corticosteroids are useful for the management
of anterior segment inﬂammation. Corticosteroids elicit nu-
merous potent anti-inﬂammatory eﬀects [6]. For instance,
they suppress cellular inﬁltration, capillary dilation, the pro-
liferation of ﬁbroblasts, collagen deposition, and eventually
scar formation; they stabilise intracellular and extracellular
membranes; and they increase the synthesis of lipocortins
that block phospholipase A2 and inhibit histamine synthesis
in the mast cells. Inhibition of phospholipase A2 prevents the
conversion of phospholipids to arachidonic acid, a critical
step in the inﬂammatory cascade. Corticosteroids also in-
crease the enzyme histaminase and modulate transcription
factors present in mast cell nuclei.
Corticosteroids mediate their anti-inﬂammatory eﬀects
primarily through the modulation of the cytosolic glucocor-
ticoid receptor (GR) at the genomic level [7, 8]. After cor-
ticosteroids bind to the GR in the cytoplasm, the activat-
edcorticosteroid-GRcomplexmigratestothenucleus,where
it upregulates the expression of anti-inﬂammatory proteins
and represses the expression of proinﬂammatory proteins.
However, recent work suggests that the activated corticoster-
oid-GR complex also elicits nongenomic eﬀects, particularly
the inhibition of vasodilation, vascular permeability, and
migration of leukocytes [7, 9]. In addition, corticoster-
oidsmediateanti-inﬂammatoryactivitythroughmembrane-
bound GR-mediated nongenomic eﬀects and through direct
nonspeciﬁc interactions with cellular membranes [9, 10].
Because the GR is involved in a plethora of signalling
pathways—in fact, more than 5000 genes are expressed or2 International Journal of Inﬂammation
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Figure 1: Mechanism of steroid-induced cataract formation adapted from [17].
suppressed following glucocorticoid exposure [11]—long-
term use or high dosages of corticosteroids can result in
adverse drug reactions (ADRs) such as increased IOP [12,
13]. Most studies implicate the involvement of trabecular
meshwork (TM) cells and myocilin gene expression in the
mechanism of corticosteroid-induced IOP increase. Steroids
decrease the outﬂow of aqueous humor by inhibiting the
degradationand/orenhancingthedepositionofextracellular
matrix material within the TM and/or cross-linking of actin
ﬁ b r e sb e t w e e nT Mc e l l s[ 14]. Structural changes in the TM,
in turn, result in corticosteroid-induced ocular hyperten-
sion, which can progress to secondary iatrogenic open-angle
glaucoma [15]. Myocilin, initially referred to as TM-in-
ducible glucocorticoid response or TIGR gene product, is a
55-kDa protein induced after exposure of TM cells to dexa-
methasone for 2-3 weeks, which is also closely associated
with decreased aqueous humor outﬂow and steroid-induced
IOP increase [16]. Diﬀerent mutations within the myocilin
gene lead to a variety of glaucoma phenotypes in both juve-
nile and adult-onset primary open-angle glaucoma, provid-
ing further evidence for its role in steroid-induced IOP [14].
Another ADR associated with corticosteroid use is the
formation of cataract. However, the mechanism of steroid-
induced cataract formation appears to be chemically based
and not likely to be related to the downstream eﬀects of
GR activation. Currently, the most prominent hypothesis
for cataract formation involves nonenzymatic formation of
Schiﬀ base intermediates between the steroid C-20 ketone
group and nucleophilic groups such as ε-amino groups of
lysine residues of lens proteins [17]. The formation of Schiﬀ
bases is followed by a Heyns rearrangement of the adjacent
C-21 hydroxyl group, resulting in stable anime-substituted
adducts (Figure 1)[ 17]. While this covalent binding mecha-
nismcouldaccountforcataractformationwithC-20ketone-
based corticosteroids, other mechanisms of steroid-induced
cataract formation may exist. Interestingly, covalent adducts
have been observed only in steroid-induced cataract, not in
other cataracts.
Further research into the mechanisms of action of ster-
oids—both for their anti-inﬂammatory eﬀects and for
ADRs—is underway. Herein, we review the design of new
corticosteroids through retrometabolic design and review
available data from preclinical and clinical studies of lote-
prednol etabonate (LE), the ﬁrst retrometabolically designed
topical steroid to reach marketing status. Studies conﬁrming
the premise of retrometabolic design are discussed.
2. Retrometabolic DrugDesign
Only a small fraction of systemically administered drugs
will distribute to the eye from the general circulation, and
an even smaller fraction thereof will cross the blood-retinal
barrier to reach the eye. Thus, topical administration of
corticosteroids is the preferred route for anterior segment
inﬂammatoryconditionsasitmaximizesdrugdeliverytothe
anterior segment and minimizes systemic exposure. Topical
administration also helps avoid systemic ADRs such as hy-
pothalamic-pituitary-adrenal-(HPA-axis) suppression. Nev-
ertheless, topical ophthalmic corticosteroids are associated
with ADRs including elevations in IOP, cataract formation
following extended use, delayed wound healing, and lower
resistance to infection [1, 7]. As previously discussed, steroid
ADRs appear to arise from the continued action of the
corticosteroid-GR complex at the genomic level beyond the
action required to elicit anti-inﬂammatory eﬀects or, in the
case of cataract formation, through formation of covalent
bonds with lens protein.
In an eﬀort to decrease ADRs, Bodor and colleagues de-
velopedtheconceptofretrometabolicdrugdesignmorethan
30yearsago[18].Theunderlyingprincipleofretrometabolic
drug design is to synthesize analogues of lead compounds or
reference compounds, starting from a known inactive meta-
boliteofthatleadcompound.Theinactivemetaboliteiscon-
verted into an isosteric/isoelectronic analogue with struc-
tural modiﬁcations designed for rapid, predictable meta-
bolism back to the original inactive metabolite after eliciting
the desired therapeutic eﬀect [19]( Figure 3). Although
Bodor named such analogues “soft drugs,” these analogues
were predicted to have therapeutic potency similar, if not
identical,tothatoftheleadcompound,but,duetothestruc-
tural modiﬁcations included by the design, any active drug
remaining following attainment of therapeutic eﬀect would
be metabolically deactivated, thus minimizing any ADRs
(hence, the “soft drug” terminology). However, the increase
in therapeutic index could only be achieved if the drug was
stable enough to reach its receptor to elicit the desired ef-
fect,whileanyfreedrugremainingthereafterwouldbemeta-
bolized to avoid ADRs. Metabolism that is too rapid wouldInternational Journal of Inﬂammation 3
ADRs
ADRs
New
compound
Retrometabolic design
Inactive metabolites
Lead
compound
Metabolism
Metabolism
Metabolism
Active metabolites
Ma1
Mi1 –
–
Mix
Max
Figure 2: Concept of retrometabolic drug design in which a new
lead compound is created based on an inactive metabolite of a pre-
vious lead compound.
Retrometabolic
drug design
Inactive
metabolite
R3 R3
OR2
OR1
9
3
1
HO
11 17 16
6
20
O
O OH
OH O
HO
O
X2 X2
X1 X1
R1 = alkyl, haloalkyl, etc.
R2 = alkyl, alkoxyalkyl, COOalkyl, etc.
R3 = H,α-o rβ-CH3
X1,X 2 = H, F
Δ1,2
Δ1,2
= double bond (present or absent)
Figure 3: Retrometabolic design of cortienic acid-based derivatives
adapted from [52].
result in decreased eﬃcacy as would poor bioavailability
and/or poor GR-binding aﬃnity. In other words, there had
to be a balance between the solubility and lipophilicity of the
drug, its tissue distribution and receptor binding, and subse-
quent rate of metabolic deactivation.
Over the years, Bodor and colleagues applied retrometa-
bolic drug design to a variety of therapeutic agents includ-
ing antimicrobials, β-blockers, analgesics, and acetylcholin-
esterase (ACE) inhibitors, with several retrometabolically
designed compounds reaching marketing application. With
respect to ocular corticosteroids, Bodor designed a number
of analogues, starting with Δ1-cortienic acid, the primary
metabolite of prednisolone, that lacks corticosteroid activity
[19](Figure 2).Toobtainnewleadcompounds,thepharma-
cophore moieties of the 17α-hydroxyl and 17β-carboxy sub-
stituents of the lead compound had to be restored by suitable
isosteric/isoelectronic substitution containing esters or other
types of functions that restored the original corticosteroid’s
anti-inﬂammatory potency while incorporating hydrolytic
features to ensure metabolism. Other structural considera-
tions included the presence/absence of double bond at the
Δ1position,ﬂuorinationat6αcarbon(X2)and/or9αcarbon
(X1), and methylation at 16α or 16β carbons (R3). Over a
hundred possible drugs were synthesized and tested in pre-
clinical anti-inﬂammatory models, and structure/activity
studies concluded that the best substitutions for maximal
activity included a haloester at the 17β position and a carbo-
nate or ether at the 17α position. 17α esters were also con-
sidered but were quickly abandoned due to their potential to
form mixed anhydrides with the haloesters, and subsequent
potentialforlensproteinbinding.Thus,inadditiontotheC-
20 ketone moiety of prednisolone being replaced to avoid the
possibility of formation of Schiﬀ base intermediates, other
chemical features associated with potential cataractogenesis
were also eliminated by design.
3.LoteprednolEtabonate
3.1. Preclinical Studies. The most promising drug candidate
among cortienic acid-based derivatives synthesized by Bodor
and colleagues was loteprednol etabonate (LE; chlorometh-
yl 17α-ethoxycarbonyloxy-11β-hydroxy-3-oxoandrosta-1,4-
diene, 17β-carboxylate) [20]. LE is the 17β-chloromethyl
ester of Δ1-cortienic acid with a 17α-etabonate moiety and
waspredictedtoundergorapiddeesteriﬁcationtoaninactive
carboxylic acid metabolite after exerting its eﬀect, thereby
minimizing the likelihood of toxicity.
Selection of LE for further development was based on a
numberofcriteria.LEishighlylipophilic—its lipophilicityis
10 times greater than that of dexamethasone, a characteristic
that may increase its eﬃcacy by enhancing penetration
through biological membranes [21]. Further, competitive
binding studies with rat lung type II GRs demonstrated that
the binding aﬃnity of LE was 4.3 times that of dexameth-
asone [22]. A vasoconstriction test in humans used to
assess bioavailability showed that LE produced a blanching
response similar to that of betamethasone 17α-valerate,
thereby conﬁrming good penetration properties and strong
potency [12]. But more importantly, initial studies by Bodor
showed that the therapeutic index of LE was more than 20-
foldbetterthanthatofothercorticosteroidsincludinghydro-
cortisone 17α-butyrate, betamethasone 17α-valerate, and
clobetasone 17α-proprionate based on the cotton pellet
granuloma test and thymolysis potency [9].
Studies in animals conﬁrmed that LE is indeed predict-
ably metabolized by local esterases into its inactive metabo-
lite, Δ1-cortienic acid. Druzgala et al. [23] studied the ocular
absorption and distribution of 14C-labelled LE 0.5% in
the eyes of rabbits. The highest concentrations of LE were
found in the cornea, followed by the iris/ciliary body and
aqueous humor. The cornea also showed the highest ratio
of metabolite to LE, indicating that the cornea was the pri-
mary site of metabolism, while aqueous humor concentra-
tions of LE were approximately 100-fold lower. This ﬁnding
suggested that LE may exert a decreased IOP eﬀect relative to
other corticosteroids, as high levels of steroids in the aque-
ous humor are thought to contribute to decrease outﬂow4 International Journal of Inﬂammation
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Figure 4: Metabolism of loteprednol etabonate.
through the TM. LE was found to have a terminal half-life
(t1/2) of 2.8 hours in dogs following intravenous administra-
tion[24].Further,whenabsorbedsystemically,LEwasfound
to be metabolized to Δ1-cortienic acid etabonate and then to
Δ1-cortienic acid (Figure 4) and eliminated rapidly through
the bile and urine [20, 25].
More importantly, a comparison of the IOP-elevating
activity of LE with that of dexamethasone in rabbits con-
ﬁrmed a lack of IOP eﬀect with LE [26]. LE and dexametha-
sone, both at 0.1% concentrations, and vehicle were instilled
topically 8 times per day for 2 days to normotensive rabbits
in a 3-way crossover design. Treatment with dexamethasone
produced an increase in IOP of ∼4mmHg after only 8 in-
stillations, while there was no signiﬁcant diﬀerence in IOP in
animals treated with LE versus those treated with vehicle.
More recently, Glogowski and Proksch [27] studied
the ocular pharmacokinetics of LE in rabbits with corneal
inﬂammation. Consistent with results obtained by Druzgala
et al., high concentrations were found in the cornea and
conjunctiva, while low levels were found in the aqueous
humor. The Cmax and AUC(0–24h) were, respectively, 3.62
(5.47)μg/mL and 6.10μg·h/g in the conjunctiva, 1.40
(1.45)μg/mL and 3.30μg·h/g in the cornea, and 0.0293
(0.00805)μg/mL and 0.0838μg·h/g in the aqueous hu-
mor. These results conﬁrm good corneal and conjunctival
penetration of LE into the anterior segment, while hydrolysis
limits signiﬁcant aqueous humor accumulation. In addition,
Samudre et al. studied the eﬃcacy of LE compared to other
corticosteroids in a model of ocular inﬂammation—lipo-
polysaccharide-induced uveitis in rabbits [28]. It was found
that LE 0.5% induced greater GR migration to the nucleus as
compared to prednisolone acetate 1% and ﬂuorometholone
0.1%. This eﬀect correlated with the disappearance of in-
ﬂammatory cells from the corneal stroma and restoration of
corneal endothelium.
Numerous additional preclinical studies have been con-
ducted to date on LE in addition to these presented here.
Taken together, they demonstrated that LE achieves the re-
quired balance between the solubility/lipophilicity, ocular
tissue distribution, receptor binding, and subsequent rate of
metabolic deactivation outlined by Bodor when he concep-
tualized retrometabolic drug design.
3.2. Clinical Studies: LE Suspension Formulations. Since
the design of LE by Bodor and colleagues, 3 ophthalmic
suspension formulations of LE have been developed and
tested clinically in various ocular inﬂammatory conditions
(Table 1) and postoperative inﬂammation (Table 2): a 0.2%
suspension, a 0.5% suspension, and a combination suspen-
sion of LE 0.5% plus tobramycin 0.3%. Clinical safety and
eﬃcacy of these formulations is brieﬂy summarized below.
Thesestudiesconﬁrmtheclinicalanti-inﬂammatorypotency
of LE and lack of signiﬁcant IOP eﬀects after its use.
Bartlett et al. [29] studied the safety and eﬃcacy of LE
0.5% in the treatment of papillae in contact lens-associated
GPC. In this 4-week study, LE-treated patients demonstrated
a signiﬁcant reduction in the primary ocular sign of GPC
(papillae, P ≤ 0.02) and were rated better in the investigator
global assessment (P = 0.017) as compared to placebo-
treated patients. The mean IOP did not change over the
course of the study. The eﬃcacy and safety of LE in the man-
agement of GPC associated with contact lens use were fur-
ther evaluated by Asbell and Howes [30] and Friedlaender
and Howes [31] in two identical studies. In both studies,
patients received 0.5% LE or placebo 4 times daily for 6
weeks. The proportion of patients with an improvement in
papillae severity and itching severity was greater in the LE
treatment group than in the placebo treatment group (P ≤
0.001). A signiﬁcant improvement in contact lens tolerance
in the LE treatment group was observed in 1 study (P =
0.002).TransientIOPelevations(≥10mmHgfrombaseline)
occurred more often in the LE treatment group but were at-
tributed to the reservoir eﬀe c to ft h ec o n t a c tl e n s ,w h i c hp a -
tients continued to wear for the duration of the study.
Dell et al. studied the eﬃcacy and safety of 0.5% LE ad-
ministered prophylactically over a period of 6 weeks before
the start of the allergy season in patients with SAC [32]. Dur-
ing peak pollen counts, the results of composite severity of
itchingandbulbarconjunctivalinjectionandtheinvestigator
global assessment signiﬁcantly favoured LE treatment (P ≤
0.001), compared with placebo. An IOP increase of greater
than10mmHgwasnotedin2patientsreceivingplaceboand
none of the patients treated with LE. The eﬃcacy of LE 0.2%
for the treatment of SAC was further evaluated by Dell et al.
[33]a n dS h u l m a ne ta l . [34] in 2 similar studies. In both
studies, LE treatment reduced bulbar conjunctival injection
and itching to a greater extent than placebo (P ≤ 0.008).
No patient experienced elevated IOP of ≥10mmHg over
baselineinonestudy,while1patientineachtreatmentgroup
experienced an IOP elevation in the second study. Recently,International Journal of Inﬂammation 5
Table 1: Loteprednol etabonate: summary of randomized, controlled, clinical safety and eﬃcacy studies in ocular Inﬂammatory diseases.
Ocular disease Treatment duration and
study treatments Eﬃcacy Safety Reference
4 weeks LE 0.5%
(n = 55) versus
placebo (n = 55)
(i) Reduced papillary severity 1–4
No change in mean
I O Pi nL Et r e a t m e n t
group [29]
(P ≤ 0.02 versus placebo)
(ii) Investigators global assessment better
(P = 0.017 versus placebo)
Giant papillary
conjunctivitis
6 weeks LE 0.5% (n = 111)
versus placebo (n = 109)
(i) Reduced papillary severity at ﬁnal visit
↑ IOP (≥10mmHg):
n = 3f o rL E
n = 0 for placebo
[30]
(P<0.001 versus placebo)
(ii) Reduced itching at ﬁnal visit
(P = 0.001 versus placebo)
(iii) Improved lens tolerance at ﬁnal visit
(P = 0.002 versus placebo)
6 weeks LE 0.5% (n = 109)
versus placebo (n = 110)
(i) Reduced papillary severity at ﬁnal visit
↑ IOP (≥10mmHg):
7% versus 0%
n = 8f o rL E
n = 0 for placebo
[31]
(P = 0.001 versus placebo)
(ii) Reduced itching at ﬁnal visit
(P<0.001 versus placebo)
(iii) Improved lens tolerance at ﬁnal visit
(P = 0.053 versus placebo)
Prophylaxis of
seasonal allergic
conjunctivitis
6 weeks LE 0.5% (n = 145)
versus placebo (n = 143)
(i) Reduced composite of itching and BCI
↑ IOP (≥10mmHg):
n = 0f o rL E
n = 2 for placebo
[32]
(P = 0.001 versus placebo)
(ii) Investigators global assessment better
(P<0.001 versus placebo)
6 weeks LE 0.2%
(n = 66) versus
placebo (n = 67)
(i) Reduced BCI, itching at 2 weeks
No ↑ IOP
(≥10mmHg) ≥1A E :
68% versus 90%
(P = 0.002)
[33]
(P ≤ 0.034 versus placebo)
(ii) Investigator global assessment at week
2b e t t e r( P<0.001 versus placebo)
Seasonal allergic
conjunctivitis
6 weeks LE 0.2% (n = 67) versus
placebo (n = 68)
(i) Reduced BCI, itching at 2 weeks ↑ IOP (≥10mmHg):
n = 1f o rL E
n = 1 for placebo
No AE: 36% versus
19% (P = 0.035)
[34]
(P ≤ 0.008 versus placebo)
(ii) Investigator global assessment at week
2b e t t e r( P<0.001 versus placebo)
2 weeks LE 0.2% (n = 151)
versus olopatadine (n = 149)
(i) Reduced BCI, itching at week 2 in No ↑ IOP
(≥10mmHg) ≥ 1
AE: 2.0% versus 1.3%
(P = NS)
[35] both groups (P ≤ 0.0006 in favour
of LE)
Anterior uveitis
6 weeks LE 0.5% (n = 36) versus
prednisolone 1.0% (n = 34)
(i) Resolution of ACC (LOCF):
↑ IOP (≥10mmHg):
n = 0f o rL E
n = 1f o r
prednisolone
[36]
74% versus 88% (P = NS)
(ii) Resolution of ﬂare (LOCF): 71%
versus 81% (P = NS)
(iii) Resolution of pain (LOCF): 79%
versus 81% (P = NS)
4 weeks LE 0.5% (n = 84) versus
prednisolone 1.0% (n = 91)
(i) Resolution of ACC (LOCF): 72%
↑ IOP (≥10mmHg):
n = 1f o rL E
n = 6f o r
prednisolone
[36]
versus 87% (P = 0.015 in favour of
prednisolone)
(ii) Resolution of ﬂare (LOCF): 66%
versus 82% (P = 0.017 in favour of
prednisolone)
(iii) Resolution of pain (LOCF): 90%
versus 85% (P = NS)6 International Journal of Inﬂammation
Table 1: Continued.
Ocular disease Treatment duration and
study treatments Eﬃcacy Safety Reference
Blepharokerato-
conjunctivitis
2 weeks LE 0.5%/tobramycin
0.3% (n = 136) versus
dexamethasone
0.1%/tobramycin 0.3%
(n = 137)
(i) Improvement from baseline in
↑ IOP (≥10mmHg):
n = 0f o rL E / T
n = 1 for DM/T Mean
IOP increase at day
15: −0.1mm Hg
versus 1.0mm Hg
(P = 0.0091) ≥ 1A E :
2.9% versus 6.5%
(P = NS)
[43]
composite signs and symptoms
severity at day 15 in both groups
(ii) LE/T noninferior to DM/T in reduced
composite signs and symptoms at day
15 (−15.2 [7.3] versus −15.6 [7.7],
P = NS)
(iii) Investigator global assessment:
43.6% versus 40.9% cured (P = NS)
2 weeks LE 0.5%/tobramycin
0.03% (n = 178) versus
dexamethasone
0.1%/tobramycin 0.3%
(n = 176)
(i) Improvement from baseline in
↑ IOP (≥10mmHg):
n = 6f o rL E / T
n = 13 for DM/T
Mean IOP increase at
day 15: 1.33mm Hg
versus 2.43mm Hg
(P = 0.0039) ≥1A E :
13.0% versus 23.2%
[44]
composite signs and symptoms
severity at day 15 in both groups
(P<0.0001 versus baseline)
(ii) LE/T noninferior to DM/T in reduced
composite signs and symptoms at day
15 (−11.6 [4.6] versus −12.4[4.7],
P = NS)
Keratoconjunctivitis
sicca
4 weeks 0.5% LE (n = 32) versus
placebo (n = 34)
(i) Reduced hyperaemia at week 2 and
week 4 (P ≤ 0.0473 versus placebo)
(ii) Subset analysis in patients with
No ↑ IOP
(≥10mmHg)
No signiﬁcant change
in mean IOP ≥1A E :
16.7% versus 23.5%
[38]
moderate-to-severe inﬂammation
at baseline
(iii) Reduced central corneal staining,
nasal bulbar conjunctival
hyperaemia, and lid margin injection
at some visits (P<0.05 versus
placebo)
LE: loteprednol etabonate, IOP: intraocular pressure, ACC: anterior chamber cells, AE: adverse event, BCI: bulbar conjunctival injection, LOCF: last
observation carried forward, NS: not signiﬁcant.
Elion-Mboussa et al. [35] compared the clinical eﬃcacy and
safety of LE 0.2% with that of an antihistamine, olopatadine
0.1%, in patients with acute SAC. It was found that LE 0.2%
was superior to olopatadine in reducing both bulbar injec-
tion and ocular itching (P ≤ 0.0006) following 2 weeks of
treatment. No patients experienced a clinically signiﬁcant in-
crease in IOP (≥10mmHg ) over baseline, suggesting that
the risk of elevated IOP with LE 0.2% may not diﬀer from
that with an antihistamine.
Two clinical studies were conducted to compare the
eﬃcacy and safety of LE 0.5% to prednisolone acetate 1.0%
in the treatment of anterior acute uveitis [36]. In the ﬁrst
study, study treatments were initially administered 8 times
daily and continued QID for up to 6 weeks. While in the sec-
ond study, study treatments were initially administered 16
times a day and continued QID for up to 4 weeks. Both treat-
mentssigniﬁcantlyreducedanteriorchambercellandﬂareas
well as pain and photophobia, compared to baseline. How-
ever, a last-observation-carried-forward analysis in the sec-
o n ds t u d ys h o w e dag r e a t e rr e d u c t i o ni nc e l la n dﬂ a r ew i t h
prednisolone than with LE (P ≤ 0.017), although no diﬀer-
ences were found at any on-treatment study visits. Across the
2 studies, only 1 LE-treated patient versus 7 prednisolone-
treated patients experienced an IOP increase of >10mmHg
over baseline (P = 0.05) [37].
LE has also been studied in the treatment of dry eye
or keratoconjunctivitis sicca. Pﬂugfelder et al. conducted a
pilot study evaluating the eﬃcacy of LE 0.5% versus placebo
for the treatment of patients with dry eyes secondary to
delayed tear clearance [38]. Although there were signiﬁcant
within-treatment improvements in the primary subjective
variable(visualanalogueseverityforworstsymptomatbase-
line) in both groups, there were no signiﬁcant within-treat-
ment improvements in the primary objective variable (com-
posite corneal staining) in either treatment group. Further
analysis of a subset of patients with moderate-to-severe in-
ﬂammation showed a signiﬁcant diﬀerence between the LE-
t r e a t e dg r o u pa n dv e h i c l e - t r e a t e dg r o u pi nc e n t r a lc o r n e a l
staining, nasal bulbar conjunctival hyperaemia, and lid mar-
gin injection at some visits (P<0.05). None of the patientsInternational Journal of Inﬂammation 7
Table 2: Loteprednol etabonate: summary of randomized, controlled, clinical safety and eﬃcacy studies in postoperative inﬂammation.
Treatment duration
and study treatments Eﬃcacy Safety Reference
2 weeks LE 0.5% (n = 109)
versus placebo (n = 113)
(i) Resolution of ACI at ﬁnal visit: 64% versus 29%
↑ IOP (≥10mmHg)
n = 3f o rL E
n = 0 for placebo
Mean IOP decreased in
both groups
≥1 AE: 58% versus 80%
(P<0.001)
[41, 42]
(P<0.001 versus placebo)
(ii) Treatment failure rate: 6% versus 30% (P<0.001
versus placebo)
(iii) Investigator global assessment of treatment eﬀect
(P<0.001 versus placebo)
(iv) Grade 0 (no pain) at ﬁnal visit: 85% versus 54%
(P = 0.003)
2 weeks LE 0.5% (n = 102)
versus placebo (n = 101)
(i) Resolution of ACI at ﬁnal visit: 55% versus 28%
↑ IOP ≥10mmHg)
n = 0f o rL E
n = 1 for placebo
Mean IOP decreased in
both groups
≥1 AE: 54% versus 75%
(P = 0.002)
[6, 42]
(P<0.001)
(ii) Treatment failure rate: 7% versus 32% (P<0.001
versus placebo)
(iii) Investigator global assessment of treatment eﬀect
(P<0.001 versus placebo)
(iv) Grade 0 (no pain) at ﬁnal visit: 83% versus 59%
(P = 0.018)
2 weeks LE 0.5% ointment
(n = 404) versus vehicle
(n = 401) [2 studies]
(i) Resolution of ACI at day 8: 27.7% versus 12.5% ↑ IOP (≥10mmHg):
n = 3f o rL E
n = 1 for vehicle
Mean IOP decreased in
both groups
Mean IOP decreased in
both groups
≥1 AE: 47.2% versus
78.0% (P<0.0001)
[45]
(P<0.0001)
(ii) Grade 0 (no pain) at day 8: 75.5% versus 43.1%
(P<0.0001)
(iii) Need for rescue medication: 27.7% versus 63.8%
(P<0.0001)
LE: loteprednol etabonate, IOP: intraocular pressure, ACI: anterior chamber inﬂammation, AE: adverse event.
experienced a clinically signiﬁcant increase in IOP follow-
ing 1 month of therapy. LE 0.5% has also been studied as
induction therapy for topical cyclosporine ophthalmic emul-
sion 0.05% in the treatment of patients with dry eye [39].
Cyclosporine improves tear production in patients with
ocular inﬂammation associated with dry eye. However, relief
ofsignsandsymptomsisoftendelayedby1to6monthsfrom
the initiation of therapy, and it has been reported that 1 in 5
patients treated with cyclosporine experiences burning and
stinging. LE induction therapy administered 2−6 months
prior to the institution of long-term cyclosporine treatment
decreased stinging and improved compliance when com-
pared with the cohort of patients who were prescribed cy-
closporine without LE induction therapy (P ≤ 0.04). A fol-
low-up study presented in abstract form indicated that 2
weeksofinduction therapywithLEwassuﬃcientto improve
subjective and objective parameters, compared to artiﬁcial
tears alone, thereby accelerating clinical improvement [40].
Two identical placebo-controlled trials examined the
safety and eﬃcacy of LE in treating postoperative inﬂamma-
tion following cataract surgery with intraocular lens implan-
tation [6, 41]. Patients were administered 1 drop of LE 0.5%
or vehicle in each eye every 4 hours, 4 times daily for up to 14
days. In both studies, greater resolution of anterior chamber
inﬂammation (the sum of anterior chamber cells and ﬂare)
was achieved with LE than with placebo (P<0.001). Results
for pain resolution, reported separately, [42] indicated that
84% of LE-treated patients, compared to 56% of vehicle-
treated patients, across the 2 studies had no pain at the ﬁnal
visit (P<0.05). The mean IOP decreased after surgery in
both the LE and placebo treatment groups.
The combination of LE 0.5% and tobramycin 0.3%
(LE/T) was evaluated in the treatment of blepharokerato-
conjunctivitis (BKC) in 2 studies [43, 44]. Both White et al.
and Chen et al. compared the safety and eﬃcacy of LE/T
with that of dexamethasone 0.1%/tobramycin 0.3% (DM/
T). Subjects in each study were randomized to LE/T or
DM/T administered 4 times daily for 14 days. Both steroid
combinations were eﬀective in improving the signs and
symptoms of BKC relative to baseline (P ≤ 0.0001). In both
studies, there were no signiﬁcant diﬀerences in the mean
change from baseline to day 15 in the signs and symptoms of
composite severity, and LE/T was found to be noninferior to
DM/T. However, in both studies, DM/T-treated patients ex-
perienced a signiﬁcant increase in the mean IOP when com-
paredwithLE/T-treatedpatients(P ≤ 0.0339).IOPincreases
of ≥10mmHg over baseline were reported more often for
the DM/T treatment group.8 International Journal of Inﬂammation
3.3. New Formulations of Loteprednol Etabonate. The safety
and eﬃcacy of LE ophthalmic ointment 0.5% (LE oint-
ment) in the treatment of inﬂammation and pain following
cataract surgery were studied in 2 randomized, multicentre,
double-masked, parallel-group, vehicle-controlled studies
[45]. Pooled analysis of the data from these studies showed
that signiﬁcantly more LE ointment-treated patients than
vehicle-treated patients had complete resolution of anterior
chamber inﬂammation and no pain at day 8 of treatment
(P<0.0001). Fewer LE ointment-treated patients required
rescue medication, and fewer had an ocular adverse event.
StudiesarealsounderwayonanewgelformulationofLE
0.5% in the treatment of inﬂammation and pain following
cataract surgery (NCT01010633 and NCT01060072). As
indicated previously, LE is highly lipophilic with limited sol-
ubility in water. A gel formulation could provide improved
product homogeneity over a suspension formulation and
perhapsamoreconsistentclinicalresponseasaconsequence.
Results of these studies are expected to be released in 2012.
4. IOP andCataractFormation with
LoteprednolEtabonate
The clinical studies summarized above conﬁrm the eﬃcacy
of LE in the treatment of ocular inﬂammatory disease and
postoperative inﬂammation associated with cataract surgery
and are supportive of LE meeting the required balance
between the solubility/lipophilicity, ocular tissue distribu-
tion, receptor binding, and subsequent rate of metabolic de-
activation, all of which are essential features of successful
retrometabolic design. Additional studies with LE, including
studies in known steroid responders, and additional study
analysesfurtherconﬁrmthereducedincidenceofADRswith
LE in clinical practice.
Holland et al. [46] compared the steroid-induced IOP
eﬀect and other ocular adverse eﬀects of LE/T with those
of DM/T in 306 healthy volunteers. In this study, patients
w e r et r e a t e d4t i m e sd a i l yf o r2 8d a y so rl o n g e r .T h en u m b e r
of patients experiencing IOP increases of ≥10mmHg from
baseline at any study visit was signiﬁcantly lower in the LE/T
group than in the DM/T group (1.95% versus 7.48%; P =
0.028); similar results were observed for mean changes from
baseline in IOP (P<0.05 at all visits). Patients in the LE/T
group were also more likely to report better ocular com-
fort/tolerability ratings relative to an artiﬁcial tear standard,
compared to subjects in the DM/T group [47].
Novack et al. [48] conducted a meta-analysis of the IOP
data from LE development studies in which patients were
treated with LE, of any concentration, for 28 days or long-
er. The analysis included a combination of 1648 healthy vol-
unteers and patients with a variety of ocular inﬂammatory
conditions. IOP elevations of ≥10mmHg over baseline oc-
curred in 1.7% (15/901) patients using LE, compared to
0.5% (3/583) patients using vehicle and 6.7% (11/164) pa-
tients using prednisolone acetate. Excluding subjects that
continued to wear soft contact lenses (allowed in the GPC
trials and thought to contribute to a reservoir eﬀect), the
rates were 0.6%, 1.0%, and 6.7% for LE, vehicle, and pre-
dnisolone acetate, respectively. Cheng et al. also conducted
a meta-analysis of LE IOP data but included data retrieved
from available published LE clinical studies [37]. A total
of 1660 patients with a variety of ocular conditions were
included in this analysis. In placebo-controlled studies, the
IOP elevation rate was 1.7% in the LE group versus 0.6% in
the placebo group (P = 0.3). In active (prednisolone) com-
parator studies, the IOP elevation rate was 0.8% in the LE
group versus 5.5% in the prednisolone group (P = 0.05).
The absence of signiﬁcant ADRs was further studied by
Ilyas et al. who studied the long-term safety of LE 0.2% by
conducting a retrospective review of 397 seasonal and peren-
nial conjunctivitis patients who had used LE 0.2% on a daily
basisforextendedperiodsoftime[49].Ofthesepatients,159
had been using LE 0.2% continuously for at least 12 months.
There were no reports of posterior subcapsular opaciﬁcation
and no clinically meaningful changes in IOP in this group.
In fact, there were no observations of IOP elevations greater
than 4mmHg over baseline at any time.
Bartlett et al. [50] compared the eﬀects of LE 0.5% and
prednisolone acetate 1.0% on IOP in a crossover study in 19
knownsteroidresponders.Studiesinknownsteroidsrespon-
d e r sa r eu s e f u ls i n c ed i ﬀerences in steroid-induced IOP
eﬀects are emphasized in this population. Subjects receiv-
ed either LE 0.5% or prednisolone 1.0% for 42 days followed
by a washout period of 14 days prior to being crossed over
to the other treatment. During LE treatment, the mean IOPs
were within the normal range, with a mean IOP elevation
of 4.1mmHg over the 42-day period (P, not signiﬁcant).
In contrast, during prednisolone treatment, the mean IOP
elevation was 9.0mmHg (P<0.05, compared to baseline)
(Figure 5). Because the study protocol required discontinua-
tion of subjects upon signiﬁcant IOP elevation, the authors
noted that the hypertensive eﬀect of prednisolone may have
been underestimated.
Finally, Holland et al. [51] reported the attenuation of
ocularhypertensioninsteroidrespondersaftercornealtrans-
plantation. In this retrospective review, 30 post-penetrating
keratoplasty and post-keratolimbal allograft patients with
IOP increases to ≥21mmHg while being treated with
prednisolone acetate 1.0% were switched to LE 0.5%.
Results showed a mean (SE) reduction of IOP from 31.1
(1.13)mmHg to 18.2 (1.37)mmHg (P = 0.0001) with no
signs of graft rejection after switching treatment from pred-
nisolone acetate to LE.
With respect to cataract formation, as indicated earlier,
Manabe et al. showed that C-20 ketone steroids such as pred-
nisolone form covalent bonds with lens protein. These au-
thors further showed that nonketolic analogues were unable
toformsuchadducts.BodorandcolleaguesdesignedLEwith
a C-20 ester rather than a C-20 ketone, and thus LE is unable
to form covalent adducts via this mechanism, although other
mechanisms of cataractogenesis cannot be ruled out. Never-
theless, the long-term study by Ilyas et al. did not suggest a
potential for cataract formation with LE. Further, a review
of global postmarketing adverse event data for LE 0.5%
revealed only 7 reports of cataract formation with LE use
(data through August 2011, Bausch & Lomb, data on ﬁle)
since product launch. During that time, an estimated 20International Journal of Inﬂammation 9
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Figure 5: Mean (SEM) IOP for subjects receiving loteprednol
etabonate and prednisolone. Within-treatment signiﬁcant changes
from baseline are indicated adapted from [50].
million LE units were distributed globally. Taken together,
thesedatasuggestthattherapidmetabolismofLEtoinactive
hydrophilic metabolites in conjunction with the lack of the
C-20 ketone have resulted in a steroid with signiﬁcantly less,
if any, potential for promoting cataract formation.
5. Conclusions
Retrometabolic drug design principles have led to the
development of LE, a C-20 ester corticosteroid. LE appears
to achieve the necessary balance between solubility/lipo-
philicity, tissue distribution, GR receptor binding, and meta-
bolic deactivation to be eﬀective as a topical ophthalmic
steroid. LE is safe and eﬀective in treating a wide variety
of ocular inﬂammatory conditions including giant papillary
conjunctivitis, seasonal allergic conjunctivitis, and uveitis as
well as in the treatment of ocular inﬂammation and pain
following cataract surgery. ADRs such as cataract formation
and IOP elevation were minimized with LE owing to its re-
trometabolic design and their absence conﬁrmed in clinical
studies.
Acknowledgments
Drs. T. L. Comstock and H. H. DeCory are employees of
Bausch & Lomb Inc. Editing assistance was provided by
CactusCommunicationsandfundedbyBausch&LombInc.
References
[1] J. Stein-Streilein and J. W. Streilein, “Anterior chamber asso-
ciated immune deviation (ACAID): regulation, biological re-
levance, and implications for therapy,” International Reviews
of Immunology, vol. 21, no. 2-3, pp. 123–152, 2002.
[2] P. Lapalus, G. Moulin, and V. Bayer, “Eﬀects of a new
anti-allergic agent: the magnesium salt of N-acetyl-aspartyl-
glutamic acid on experimental allergic inﬂammation of the
rabbit eye,” Current Eye Research, vol. 5, no. 7, pp. 517–522,
1986.
[3] V. M. G. Ferguson and D. J. Spalton, “Recovery of the blood-
aqueous barrier after cataract surgery,” British Journal of
Ophthalmology, vol. 75, no. 2, pp. 106–110, 1991.
[ 4 ] M .B .A b e l s o na n dK .S c h a e f e r ,“ C o n j u n c t i v i t i so fa l l e r g i co r i -
gin: immunologic mechanisms and current approaches to
therapy,” Survey of Ophthalmology, vol. 38, pp. 115–132, 1993.
[5] S.L.ChamblessandS.T r ocme,“Dev elopmentsinocularaller -
gy,” Current Opinion in Allergy and Clinical Immunology, vol.
4, no. 5, pp. 431–434, 2004.
[6] G. D. Novack, “A double-masked, placebo-controlled evalua-
tion of 0.5% loteprednol etabonate in the treatment of post-
operative inﬂammation,” Ophthalmology, vol. 105, no. 9, pp.
1780–1786, 1998.
[7] T. Rhen and J. A. Cidlowski, “Antiinﬂammatory action of glu-
cocorticoids—new mechanisms for old drugs,” New England
Journal of Medicine, vol. 353, no. 16, pp. 1711–1658, 2005.
[8] R. Newton, “Molecular mechanisms of glucocorticoid action:
what is important?” Thorax, vol. 55, no. 7, pp. 603–613, 2000.
[9] C. Stahn and F. Buttgereit, “Genomic and nongenomic eﬀects
ofglucocorticoids,”NatureClinicalPracticeRheumatology,vol.
4, no. 10, pp. 525–533, 2008.
[10] C. Stahn, M. L¨ o w e n b e r g ,D .W .H o m m e s ,a n dF .B u t t g e r e i t ,
“Molecular mechanisms of glucocorticoid action and selective
glucocorticoid receptor agonists,” Molecular and Cellular
Endocrinology, vol. 275, no. 1-2, pp. 71–78, 2007.
[11] J. A. Cidlowski, “Glucocorticoids and their actions in cells,”
Retina, vol. 29, no. 6, pp. S21–S23, 2009.
[12] H. Sch¨ acke, W.-D. D¨ ocke, and K. Asadullah, “Mechanisms
involved in the side eﬀects of glucocorticoids,” Pharmacology
and Therapeutics, vol. 96, no. 1, pp. 23–43, 2002.
[13] C. N. J. McGhee, S. Dean, and H. Danesh-Meyer, “Locally
administered ocular corticosteroids beneﬁts and risks,” Drug
Safety, vol. 25, no. 1, pp. 33–55, 2002.
[14] J.P.KerseyandD.C.Broadway,“Corticosteroid-inducedglau-
coma: a review of the literature,” Eye, vol. 20, no. 4, pp. 407–
416, 2006.
[15] A.F.ClarkandR.J.Wordinger,“Theroleofsteroidsinoutﬂow
resistance,” Experimental Eye Research, vol. 88, no. 4, pp. 752–
759, 2009.
[16] E. L¨ utjen-Drecoll, C. A. May, J. R. Polansky, D. H. Johnson,
H. Bloemendal, and T. D. Nguyen, “Localization of the stress
proteins αB-crystallin and trabecular meshwork inducible
glucocorticoid response protein in normal and glaucomatous
trabecular meshwork,” Investigative Ophthalmology and Visual
Science, vol. 39, no. 3, pp. 517–525, 1998.
[17] S. Manabe, R. Bucala, and A. Cerami, “Nonenzymatic addi-
tion of glucocorticoids to lens proteins in steroid-induced
cataracts,” Journal of Clinical Investigation,v o l .7 4 ,n o .5 ,p p .
1803–1810, 1984.
[18] N. Bodor, E. Shek, and T. Higuchi, “Improved delivery
through biological membranes. 1. Synthesis and properties
of 1-methyl-1,6-dihydropyridine-2-carbaldoxime, a pro-drug
of N-methylpyridinium-2-carbaldoxime chloride,” Journal of
Medicinal Chemistry, vol. 19, no. 1, pp. 102–107, 1976.
[19] N. Bodor and P. Buchwald, “Soft drug design: general princi-
ples and recent applications,” Medicinal Research Reviews, vol.
20, no. 1, pp. 58–101, 2000.
[20] N. Bodor, T. Loftsson, and W. Wu, “Metabolism, distribution,
and transdermal permeation of a soft corticosteroid, lotepred-
nol etabonate,” Pharmaceutical Research, vol. 9, no. 10, pp.
1275–1278, 1992.
[21] M. Alberth, W. M. Wu, D. Winwood, and N. Bodor, “Lipo-
philicity, solubility and permeability of loteprednol etabonate:10 International Journal of Inﬂammation
a novel, soft anti-inﬂammatory steroid,” Journal of Biophar-
maceutical Sciences, vol. 2, pp. 115–125, 1991.
[22] P. Druzgala, G. Hochhaus, and N. Bodor, “Soft drugs—10.
Blanching activity and receptor binding aﬃnity of a new type
of glucocorticoid: loteprednol etabonate,” Journal of Steroid
Biochemistry and Molecular Biology, vol. 38, no. 2, pp. 149–
154, 1991.
[23] P. Druzgala, W. M.Wu, and N. Bodor,“Ocular absorptionand
distribution of loteprednol etabonate, a soft steroid, in rabbit
eyes,” Current Eye Research, vol. 10, no. 10, pp. 933–937, 1991.
[24] G. Hochhaus, L. S. Chen, A. Ratka et al., “Pharmacokinetic
characterization and tissue distribution of the new glucocorti-
coid soft drug loteprednol etabonate in rats and dogs,” Journal
of Pharmaceutical Sciences, vol. 81, no. 12, pp. 1210–1215,
1992.
[25] N.Bodor,W.M.Wu,T.Mrakami,andS.Engel,“Softdrugs19.
Pharmacokinetics, metabolism and excretion of a novel soft
corticosteroid, loteprednol etabonate, in rats,” Pharmaceutical
Research, vol. 12, no. 6, pp. 875–879, 1995.
[26] N.Bodor,N.Bodor,andW.M.Wu,“Acomparisonofintraoc-
ular pressure elevating activity of loteprednol etabonate and
dexamethasone in rabbits,” Current Eye Research, vol. 11, no.
6, pp. 525–530, 1992.
[27] S. Glogowski and J. Proksch, “Ocular pharmacokinetics of
loteprednol etabonate following ocular administration of a
novel ointment formulation or a suspension (Lotemax)
in rabbits with corneal inﬂammation,” in Proceedings of the
Association for Research in Vision and Ophthalmology Meeting,
Ft. Lauderdale, Fla, USA, 2010.
[28] S. S. Samudre, F. A. Lattanzio, P. B. Williams, and J. D.
Sheppard, “Comparison of topical steroids for acute anterior
uveitis,” Journal of Ocular Pharmacology and Therapeutics, vol.
20, no. 6, pp. 533–547, 2004.
[ 2 9 ]J .D .B a r t l e t t ,J .F .H o w e s ,N .R .G h o r m l e y ,J .F .A m o s ,R .
Laibovitz, and B. Horwitz, “Safety and eﬃcacy of loteprednol
etabonate for treatment of papillae in contact lens-associated
giant papillary conjunctivitis,” Current Eye Research, vol. 12,
no. 4, pp. 313–321, 1993.
[30] P. Asbell and J. Howes, “A double-masked, placebo-controlled
evaluation of the eﬃcacy and safety of loteprednol etabonate
in the treatment of giant papillary conjunctivitis,” CLAO
Journal, vol. 23, no. 1, pp. 31–36, 1997.
[31] M. H. Friedlaender and J. Howes, “A double-masked, placebo-
controlled evaluation of the eﬃcacy and safety of loteprednol
etabonate in the treatment of giant papillary conjunctivitis,”
American Journal of Ophthalmology, vol. 123, no. 4, pp. 455–
464, 1997.
[ 3 2 ]S .J .D e l l ,D .G .S h u l m a n ,G .M .L o w r y ,a n dJ .H o w e s ,“ Ac o n -
trolled evaluation of the eﬃcacy and safety of loteprednol eta-
bonate in the prophylactic treatment of seasonal allergic con-
junctivitis,” American Journal of Ophthalmology, vol. 123, no.
6, pp. 791–797, 1997.
[ 3 3 ]S .J .D e l l ,G .M .L o w r y ,J .A .N o r t h c u t t ,J .H o w e s ,G .D .
Novack, and K. Hart, “A randomized, double-masked, place-
bo-controlled parallel study of 0.2% loteprednol etabonate
in patients with seasonal allergic conjunctivitis,” Journal of
Allergy and Clinical Immunology, vol. 102, no. 2, pp. 251–255,
1998.
[34] D. G. Shulman, L. L. Lothringer, J. M. Rubin et al., “A ran-
domized, double-masked, placebo-controlled parallel study of
loteprednol etabonate 0.2% in patients with seasonal allergic
conjunctivitis,” Ophthalmology, vol. 106, no. 2, pp. 362–369,
1999.
[35] A. Elion-Mboussa, L. Gong, L. Roy, B. Zhu, H. DeCory, and
E. Chu, “Loteprednol etabonate ophthalmic suspension, 0.2%
is as safe as olopatadine hydrochloride ophthalmic solution,
0.1% with superior relief of signs and symptoms in the
treatment of seasonal allergic conjunctivitis,” in Proceedings of
the Annual Meetingofthe AmericanAcademyof AllergyAsthma
and Immunology, Orlando, Fla, USA, March 2012.
[36] C.R.Cohen,J.Davis,R.DeBargeetal.,“Controlledevaluation
of loteprednol etabonate and prednisolone acetate in the
treatment of acute anterior uveitis,” American Journal of
Ophthalmology, vol. 127, no. 5, pp. 537–544, 1999.
[37] J. W. Cheng, R. L. Wei, and Y. Li, “Safety and eﬃcacy of lote-
prednol for ocular inﬂammation: a meta-analysis,” Chinese
Journal of New Drugs and Clinical Remedies, vol. 22, no. 5, pp.
259–263, 2003.
[38] S. C. Pﬂugfelder, S. L. Maskin, B. Anderson et al., “A rando-
mized, double-masked, placebo-controlled, multicenter com-
parison of loteprednol etabonate ophthalmic suspension,
0.5%, and placebo for treatment of keratoconjunctivitis sicca
in patients with delayed tear clearance,” American Journal of
Ophthalmology, vol. 138, no. 3, pp. 444–457, 2004.
[39] J. D. Sheppard, S. V. Scoper, and S. Samudre, “Topical lote-
prednolpretreatmentreducescyclosporinestinginginchronic
dry eye disease,” Journal of Ocular Pharmacology and Thera-
peutics, vol. 27, no. 1, pp. 23–27, 2011.
[40] E.Donnenfeld,J.D.Sheppard,andE.J.Holland,“Prospective,
multicenter, randomized controlled study on the eﬀect of
loteprednol etabonate on initiating therapy with cyclosporine
A,” in Proceedings of the American Academy of Ophthalmology
Annual Meeting, New Orleans, La, USA, November 2007.
[41] R. Stewart, B. Horwitz, J. Howes et al., “Double-masked,
placebo-controlled evaluation of loteprednol etabonate 0.5%
for postoperative inﬂammation,” Journal of Cataract and Re-
fractive Surgery, vol. 24, no. 11, pp. 1480–1489, 1998.
[ 4 2 ]T .L .C o m s t o c ka n dD .W .U s n e r ,“ E ﬀect of loteprednol eta-
bonate ophthalmic suspension 0.5% on post-operative pain
and discomfort,” in Proceedings of the American Society of Cat-
aract and Refractive Surgery Meeting, 2010.
[43] E. M. White, J. I. Macy, K. M. Bateman, and T. L. Com-
stock, “Comparison of the safety and eﬃcacy of lotepred-
nol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobra-
mycin 0.3% in the treatment of blepharokeratoconjunctivitis,”
Current Medical Research and Opinion, vol. 24, no. 1, pp. 287–
296, 2008.
[44] M. Chen, L. Gong, X. Sun et al., “Comparison of the safety
and eﬃcacy of loteprednol etabonate 0.5% tobramycin 0.3% 5
with dexamethasone 0.1%/tobramycin 0.3% in the treatment
of Chinese patients with blepharokeratoconjunctivitis,” Cur-
rent Medical Research Opinion. In press.
[45] T. L. Comstock, M. R. Paterno, A. Singh, T. Erb, and E. Davis,
“Safety and eﬃcacy of loteprednol etabonate ophthalmic
ointment 0.5% for the treatment of inﬂammation and pain
following cataract surgery,” Clinical Ophthalmology, vol. 5, no.
1, pp. 177–186, 2011.
[46] E. J. Holland, J. D. Bartlett, M. R. Paterno, D. W. Usner,
a n dT .L .C o mst oc k ,“ Eﬀects of loteprednol/tobramycin versus
dexamethasone/tobramycinonintraocularpressureinhealthy
volunteers,” Cornea, vol. 27, no. 1, pp. 50–55, 2008.
[47] J. D. Bartlett, E. J. Holland, D. W. Usner, M. R. Paterno, and T.
L. Comstock, “Tolerability of loteprednol/tobramycin versus
dexamethasone/tobramycin in healthy volunteers: results of
a 4-week, randomized, double-masked, parallel-group study,”
CurrentMedicalResearchandOpinion,vol.24,no.8,pp.2219–
2227, 2008.International Journal of Inﬂammation 11
[ 4 8 ]G .D .N o v a c k ,J .H o w e s ,R .S .C r o c k e t t ,a n dM .B .S h e r w o o d ,
“Change in intraocular pressure during long-term use of lote-
prednoletabonate,”JournalofGlaucoma,vol.7,no.4,pp.266–
269, 1998.
[49] H. Ilyas, C. B. Slonim, G. R. Braswell, J. R. Favetta, and M.
Schulman, “Long-term safety of loteprednol etabonate 0.2%
in the treatment of seasonal and perennial allergic conjun-
ctivitis,” Eye and Contact Lens, vol. 30, no. 1, pp. 10–13, 2004.
[ 5 0 ]J .D .B a r t l e t t ,B .H o r w i t z ,R .L a i b o v i t z ,a n dJ .F .H o w e s ,“ I n -
traocularpressureresponsetoloteprednoletabonateinknown
steroidresponders,”JournalofOcularPharmacology,vol.9,no.
2, pp. 157–165, 1993.
[51] E. J. Holland, A. R. Djalilian, and J. P. Sanderson, “Attenuation
of ocular hypertension with the use of topical loteprednol eta-
bonate 0.5% in steroid responders after corneal transplanta-
tion,” Cornea, vol. 28, no. 10, pp. 1139–1143, 2009.
[52] N. Bodor and P. Buchwald, “Ophthalmic drug design based
on the metabolic activity of the eye: soft drugs and chemical
delivery systems,” AAPS Journal, vol. 7, no. 4, article 79, 2005.